Background: The relationship between survivin and extranodal, nasal-type natural killer/T cell lymphoma (ENKTCL) was unclearly established yet. We here studied the potential prognostic roles of survivin and its implication as a target in ENKTCL therapy.
Introduction
Extranodal, nasal-type natural killer/T cell lymphoma (ENKTCL) is a special subtype of non-Hodgkin's lymphoma with a geographical and ethnical predilection for Asian and South American populations. A conservative estimate in China is that 11.0% of malignant lymphomas newly diagnosed each year are ENKTCL, the second large proportion among all types of lymphoma (1) . Up to 60-80% of patients were classified as Ann Arbor Stage I/II at the time of initial diagnosis. However, the traditional and classical chemotherapy CHOP was administrated in these stage I/II patients, the 5-year overall survival (OS) was less than 50%. For those patients of stage III/IV or relapsed and/or refractory disease, 1-year OS was just only 55% (2) . Some new therapy regimens, composing of L-asparaginase, cisplatin, carboplatin, oxaliplatin, ifosfamide, methotrexate, etoposide, gemcitabine, and/or dexamethasone, showed a promising overall response rate (81-100%) and a 2-3-year OS (78-87.5%) in stage I/II patients (3) (4) (5) (6) (7) . But 5-year OS was only about 60% and much less than that of other types of early lymphomas (8, 9) . Development of new effective drugs is thus desired to improve the survival of ENKTCL patients.
Survivin belongs to the family of inhibitors of apoptosis proteins (IAPs). In normal situation, survivin is prominently expressed during embryonic development and absently or little expressed in normal differentiated adult tissues. But survivin expression is abnormally upregulated in cells transformed into malignancy. Over-expression of survivin was closely associated with cancer cells proliferation, apoptosis, autophagy, anti-cancer-drugs resistance, and cancer angiogenesis (10) (11) (12) (13) (14) (15) (16) . In addition, high level of survivin was detected in peripheral blood of patients with some kinds of cancers and might be a good marker for prognosis (17) (18) (19) (20) .
Due to the important roles of survivin in malignancies, drug development targeting survivin may yield cumulative benefits. YM155, as one of the low molecular weight antagonists, inhibits the gene transcription through binding with the Sp1 of survivin promoter. Some researches claimed that YM155 alone or combined with other anti-cancer drugs can inhibit proliferation, increase apoptosis, reverse drug resistance, and improve radiation sensitivity of cancer cells (21) (22) (23) (24) . A few phases I/II clinical trials were operated in advanced cancer patients to test the safety and tolerance of YM155 (25) (26) (27) (28) .
There were a couple of reports about the association between ENKTCL and survivin. The positive survivin expression in ENKTCL tissue samples from Singapore was 97% (22/23) (29) . The positive rate of serum survivin in ENKTCL from Korea was 27.3% and significantly correlated with the level of EBV-DNA, tumor loading and OS (30) . However, the roles of survivin in ENKTCL were not clearly understood yet. We here aimed to further study survivin as a therapy target for ENKTCL. 
Methods

Patients and samples
Cell line and reagents
The human NKTCL cell line SNK-10 was obtained from Fudan University (Shanghai) and cultured in RPMI1640 (Thermo Scientific) supplemented with 15% heat-inactivated human serum, 700 IU/mL of IL-2, 1 0 0 U / m L o f p e n i c i l l i n s o d i u m , 1 0 0 m g / m L o f streptomycin sulfate, and 0.5 μg/mL amphotericin B at 37 ℃ in a humidified air atmosphere containing 5% CO 2 . The cell line was authenticated by testing membrane markers using flow cytometry (31) . YM155 monobromide (YM155) was purchased from Selleck Chemicals Company and dissolved in dimethyl sulfoxide (DMSO), DDP from Qilu Pharmaceutical Co., Ltd.
ELISA
The blood was placed in room temperature for 4 hours for being fully solidified, and was centrifuged by 3,500 rpm/min. The serum samples were then sub-packaged and stored at −80 ℃ until tested for levels of survivin. An ELISA Kit (Human Survivin ELISA kit, Abcam) was used to determine the concentration of survivin in the serum samples. The instruction was carefully followed.
Establishment of BIRC5 co-regulated Cluster
Gene expression profiles of 51 samples were obtained from the ArrayExpress Archive under E-TABM-702, including 7 ENKTCL biopsies, 2 ENKTCL cell lines, 16 PTCL NOS biopsies, 6 normal NK-cells, and 20 normal B-cell samples (32) . We removed those genes with both coefficient of variation and quartile coefficient of dispersion across all samples less than 0.15. Total 11,254 genes were left for following analysis.
MTT assay
In vitro cell proliferation was measured using MTT assay. Cells in the logarithmic phase of growth were seeded into 96-well culture plates at 1×10 4 cells per well. After treatment with different concentrations of YM155, or vehicle control, or different concentration combinations of YM155 with DDP, 100 μL of MTT solution (1 mg/mL) were added to each well, and the cells were further incubated at 37 ℃ for 4 hours. The supernatant was replaced with dimethyl sulfoxide (DMSO) to dissolve formazan production. The absorbance at wave length 570 nm was measured and 630 nm adjusted using micro-ELISA reader. The inhibition rates were calculated from 3 independent assays.
Flow cytometry
After YM155 treatment, cells were collected and fixed in chilled 70% ethanol, resuspended in PBS, and treated with RNaseA. Propidium iodide (PI) was added to cells, and samples were analyzed with flow cytometry in FACSCalibur (BD Biosciences). Cell-cycle profile analysis of DNA histograms of integrated red fluorescence was performed with ModFit LT software (VeritySoftware, Inc, Topsham). Mean values were obtained from three independent assays.
Analysis for synergy
The Bliss Additivism model was used to classify the effect of combining two agents as additive, synergistic, or antagonistic. A theoretical curve was calculated for combined inhibition using the equation: 
Statistical analysis
Kaplan Meier plot was used to demonstrate survival time.
Pearson coefficient was used to analyze the correlation. The coupled two-way clustering algorithm was used to obtain a stable cluster (33) . The molecular signatures database was used for the gene set enrichment analysis (34) , and the principle component analysis was used to visually and globally characterize the difference among various types of samples. Probit analysis (Logit model) was used to evaluate the half maximal inhibitory concentration (IC50) of agents. Inhibition rates were calculated as the means of at least three different experiments ± standard deviation (SD). The results were analyzed by one-way ANOVA, and P<0.05 was considered to be statistically significant.
Ethics approval
This study was conducted in State Key Laboratory of Biotherapy (SKLB), Sichuan University which was established by the Ministry of Sciences and Technology in China. SKLB is a highly-regarded, comprehensive and multidisciplinary research center in China. Through the seamless integration of basic research, preclinical development, translational and clinical medicine, an efficient and fully integrated technology chain for the discovery and development of innovative drug candidates has been established in a single institute. It has been exempted from ethics as a primary research project.
Results
Serum survivin level in ENKTCL patients
Peripheral venous blood of 17 patients, who were diagnosed as ENKTCLs with their primary sites in the upper aerodigestive tract according to the WHO criteria, were collected. The correlations between patients' clinical characteristics and the level of serum survivin were shown in Table 1 . Their averaged age was 44.9 years (ranged from 15 to 74 years). Three of them (17.6%) were positive of serum survivin. Their concentrations were 56.22, 13.89, and 21.03 pg/mL, respectively. The survivin level was negatively correlated with OS (R=−0.644, P=0.005), and positively correlated with the level of serum lactic dehydrogenase (LDH) (R=0.627, P=0.007). The serum survivin was negative in all 16 donators.
Survival analysis
Up to the following-up deadline (12/2015), the median survival time of patients was 2.8 years with range from 0.4 to 7.2 years. For all patients, 2-year OS was 58.8%, and 3-year OS was 44.1% ( Figure 1A) . Among eight dead patients (47.1%), three of them had positive serum survivin. Their survival times were typically short, being 0.4, 0.6 and 1.5 years, respectively. In negative survivin group, 2-and 3-year OS was 71.4%, and 53.6% respectively, clearly higher than those of overall patients. The survival difference between survivin positive and negative patients was statistically significant (P<0.001), that was, survival time of patients with negative was significantly longer than that of positive patients ( Figure 1B) .
The role of survivin co-regulated gene set
By using the coupled two-way clustering algorithm, we observed that BIRC5 (survivin gene) belonged to a large stable cluster (G72) with 4,419 genes, which could hardly differentiate between ENKTCL (S5) and normal NK-cell samples (S4) ( Figure S1 ). To identify a systematic cluster of genes which are putatively co-regulated with survivin in ENKTCL, we considered only those ENKTCL biopsies and normal NK-cell samples. A stable 139-gene cluster ( Table S1 ) was putatively survivin co-regulated because of their highly correlation of expressions (Figure 2A ). By the principle component analysis, we noticed that ENKTCL was close to the activated NK-cells compared to the resting NK-cells ( Figure 2B ). Gene set enrichment analysis over this cluster also indicated that ENKTCLs were more activated, less differentiated, and earlier-effector-like than NK-cells ( Table 2 ). According to the gene ontology analysis, this cluster was enriched with cell cycle and proliferation genes, consistent with the survivin functions. Additionally, it was significantly related to pluripotency and drug resistances. All of them suggested that survivin was involved in the process of ENKTCL ( Table 2) .
Anti-tumor effect of YM155 alone and combined with Cisplatinum (DDP)
As shown in Figure 3A ,B, YM155 alone had a strong anti-tumor effect in a dose dependent manner. Basically, the higher dose was applied, the higher inhibition rate was observed. When the dose went up to 50 nm/L or above, there was a big jump of inhibition rate following time extending, almost reaching 100% inhibition at 48 h. Statistically, both of time and dose were correlated to inhibition rate (P<0.001). Figure 3C ,D showed that YM155 treatment increased sub-G1 phase population, and reduced G1-and G2-M phase populations significantly (P<0.05).
We then investigated the anti-tumor effect of YM155 combined with DDP. The IC50 was 17.47±4.82 nm/L for YM155 and 1.54±0.1 μg/mL for DDP. The dosages of YM155 combined with DDP were determined according to the IC50. The percentage of cell growth inhibition induced by combination of YM155 with DDP was much higher than either agent alone, even higher than the Bliss index ( Figure 4) , declaring that YM155 and DDP were synergistic.
Discussion
Survivin plays an important role in many kinds of malignant tumors. For example, atypical survivin level was reported in peripheral blood of pancreatic cancer patients and might act as a diagnostic and prognostic marker (19) . The patients were shown to have obviously higher survivin than that of normal adults, with a median concentration of 99.4 pg/mL in patients and 41.36 pg/mL in normal adults (P<0.001).
Higher level of serum survivin was significantly associated with perineural invasion, venous invasion, lymph node status (N stage), cell differentiation, and recurrence. Median OS of normal serum survivin group was much longer than that of elevated group (26 vs. 9 months), and 5-year OS was 38.4% for the normal serum survivin group and 9.3% for the high serum survivin group, indicating that survivin was an independent prognostic factor for pancreatic cancer. Similar results were also reported in gallbladder cancer, breast cancer and ovarian cancer, with the median value of survivin being 4.1-112.4 pg/mL (17, 18, 20) . (30) . In our study, the positive rate of survivin was 17.6% in ENKTCL patients' serum (ranged from 13.9 to 56.22 pg/mL). And the level of serum survivin was also negatively correlated to OS. Patients with negative survivin had longer survival time than those with positive survivin. Otherwise, we found that serum survivin has significant association with serum LDH. Because high serum LDH is well known to be a worse factor for non-Hodgkin lymphoma' prognosis, we inferred that survivin should be a factor for poor outcome of ENKTCL patients. Above all, different concentration of serum survivin were reported by different researches over virous cancers (median value ranged from 4.1 to 176 pg/mL) and the positive detection rate was low, suggesting that survivin still needs to be further studied as a prognostic marker in clinic. A unified protocol and samples from multiple resources were desired for further researches.
At mRNA level, cell-free BIRC5 (survivin-encoded gene) was found to be significantly increased in serum of colorectal cancer (CRC), and closely correlated with tumor differentiation, regional lymph node metastasis and TNM stage. High serum BIRC5 mRNA expression corresponded to a poorer OS (35) . These prompted that serum BIRC5 mRNA may be an interesting target for ENKTCL as well.
To further characterize the roles of survivin in ENKTCL, transcriptomic profiles were collected from the ArrayExpress Archive under E-TABM-702 (32) . We obtained a stable 139-gene cluster which was supposed to be BIRC5 co-regulated. This cluster was enriched with genes related to pluripotency and drug resistances, in addition to the expected cell cycle and proliferation, strongly supporting that BIRC5 should be one of the targets critical for ENKTCL transformation and development. We also found that ENKTCL cells were maintained on a more <1E-6 Up-regulation of these genes in patients with nonsmall cell lung cancer predicts poor survival outcome activated, less differentiated, and earlier-effector-like stage compared to normal NK-cells. Therefore, BIRC5 might be involved in maintaining this pluripotency, activation, and undifferentiation within ENKTCL cells. BIRC5 inhibitor might be one of the potential drugs for ENKTCL treatment. YM155, one of survivin inhibitors, inhibits survivin gene expression by suppressing promoter activity. It showed multiple functions such as anti-tumor proliferation and inducing apoptosis in cancer cell lines. It could also increase the sensitivity of radiotherapy and reverse drug-resistance. For example, YM155 in combination with bendamustine/ rituximab showed a greater therapeutic efficacy than either agent alone, induced a greater sub-G1 phase population, and made a survival time extension in DLBCL xenografts (22) . YM155 sensitized ovarian cancer to DDP, osteosarcoma to doxorubicin and CRC to 5-Fu (24, 36, 37) . The safety and feasibility of YM155 were reported in phase I/II clinical trials in patients with refractory/recurrence lymphoma and solid malignances (25) (26) (27) (28) . But not ENKTCL yet. In this study, our results showed that YM155 resulted a greater sub-G1 population, depressed ENKTCL cells proliferation and induced apoptosis and necrosis. Our results demonstrated that the combination effect of YM155 and DDP was synergistic, suggesting that YM155 combined with DDP was potential regimen for advanced/refractory 
Conclusions
This research has shown that survivin was a prognostic marker for the ENKTCL patients and a key regulatory molecule in the pathological process of ENKTCL. Survivin was also proved to be a promising target in the drug discovery for ENKTCL. 
